Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.63 |
| ▸ | ESR1 | P03372 | 2/20 | 0.63 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.48 |
| ▸ | WIZ | O95785 | 1/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30903867 | 0.93 | CRBN (0.56) | CRBNESR1IKZF2IKZF3AR | |
| SCHEMBL20046361 | 0.93 | CRBN (0.66) | CRBNESR1IKZF2CSNK1A1WIZ | |
| SCHEMBL29596744 | 0.91 | CRBN (0.56) | CRBNESR1IKZF2CSNK1A1WIZ | |
| SCHEMBL29597401 | 0.91 | CRBN (0.56) | CRBNESR1IKZF2CSNK1A1IKZF3 | |
| SCHEMBL29596359 | 0.91 | CRBN (0.57) | CRBNESR1IKZF2CSNK1A1IKZF3 | |
| SCHEMBL30984796 | 0.90 | CRBN (0.64) | CRBNESR1IKZF2WIZ | |
| SCHEMBL25079658 | 0.89 | CRBN (0.71) | CRBNESR1IKZF2CSNK1A1WIZ | |
| SCHEMBL20046362 | 0.88 | CRBN (0.59) | CRBNESR1IKZF2CSNK1A1WIZ | |
| SCHEMBL30906253 | 0.87 | CRBN (0.63) | CRBNESR1IKZF2CSNK1A1WIZ | |
| SCHEMBL30903876 | 0.86 | CRBN (0.49) | CRBNESR1IKZF2CSNK1A1WIZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024102784-A1 | SUBSTITUTED QUINOLINONE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-05-16 | — | — | WO | disclosed |